These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 18282481)
21. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Lara E; Mai A; Calvanese V; Altucci L; Lopez-Nieva P; Martinez-Chantar ML; Varela-Rey M; Rotili D; Nebbioso A; Ropero S; Montoya G; Oyarzabal J; Velasco S; Serrano M; Witt M; Villar-Garea A; Imhof A; Mato JM; Esteller M; Fraga MF Oncogene; 2009 Feb; 28(6):781-91. PubMed ID: 19060927 [TBL] [Abstract][Full Text] [Related]
22. [Sirtuins--modulation of their activity as a novel therapeutic target]. Kucińska M; Piotrowska H; Murias M Pol Merkur Lekarski; 2010 Mar; 28(165):231-5. PubMed ID: 20815175 [TBL] [Abstract][Full Text] [Related]
23. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. Smith BC; Denu JM Biochemistry; 2007 Dec; 46(50):14478-86. PubMed ID: 18027980 [TBL] [Abstract][Full Text] [Related]
24. Sirtuins and p53. van Leeuwen I; Lain S Adv Cancer Res; 2009; 102():171-95. PubMed ID: 19595309 [TBL] [Abstract][Full Text] [Related]
28. An overview of Sirtuins as potential therapeutic target: Structure, function and modulators. Wang Y; He J; Liao M; Hu M; Li W; Ouyang H; Wang X; Ye T; Zhang Y; Ouyang L Eur J Med Chem; 2019 Jan; 161():48-77. PubMed ID: 30342425 [TBL] [Abstract][Full Text] [Related]
29. Sirtuin functions and modulation: from chemistry to the clinic. Carafa V; Rotili D; Forgione M; Cuomo F; Serretiello E; Hailu GS; Jarho E; Lahtela-Kakkonen M; Mai A; Altucci L Clin Epigenetics; 2016; 8():61. PubMed ID: 27226812 [TBL] [Abstract][Full Text] [Related]
31. An in silico approach to discovering novel inhibitors of human sirtuin type 2. Tervo AJ; Kyrylenko S; Niskanen P; Salminen A; Leppänen J; Nyrönen TH; Järvinen T; Poso A J Med Chem; 2004 Dec; 47(25):6292-8. PubMed ID: 15566299 [TBL] [Abstract][Full Text] [Related]
32. Sirtuins: novel targets for metabolic disease in drug development. Jiang WJ Biochem Biophys Res Commun; 2008 Aug; 373(3):341-4. PubMed ID: 18577374 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. Suzuki T; Khan MN; Sawada H; Imai E; Itoh Y; Yamatsuta K; Tokuda N; Takeuchi J; Seko T; Nakagawa H; Miyata N J Med Chem; 2012 Jun; 55(12):5760-73. PubMed ID: 22642300 [TBL] [Abstract][Full Text] [Related]
34. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. Albani D; Polito L; Forloni G J Alzheimers Dis; 2010; 19(1):11-26. PubMed ID: 20061622 [TBL] [Abstract][Full Text] [Related]
36. New assays and approaches for discovery and design of Sirtuin modulators. Schutkowski M; Fischer F; Roessler C; Steegborn C Expert Opin Drug Discov; 2014 Feb; 9(2):183-99. PubMed ID: 24382304 [TBL] [Abstract][Full Text] [Related]
37. Sirtuins as possible targets in neurodegenerative diseases. Donmez G Curr Drug Targets; 2013 Jun; 14(6):644-7. PubMed ID: 23410123 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Suzuki T; Imai K; Imai E; Iida S; Ueda R; Tsumoto H; Nakagawa H; Miyata N Bioorg Med Chem; 2009 Aug; 17(16):5900-5. PubMed ID: 19616958 [TBL] [Abstract][Full Text] [Related]